Healthcare / BiotechnologyKOSDAQ
$28800.00
+1150.00 (+4.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.4B · quality 74.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.07T
P/E
N/A
•EV/EBITDA
N/A
•ROE
-88.3%
↓Gross Margin
13.3%
↓Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.2%
FCF CAGR
—
FCF margin
-463.6%
FCF / Net income
1.08x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.98B · net income $-30.05B · FCF $-32.37B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.98B | $6.98B | $9.18B | $9.03B | $8.47B |
| Net Income | $-30.05B | $-30.05B | $-24.11B | $-21.12B | $-25.46B |
| EBITDA | $-29.99B | $-29.99B | $-24.10B | $-21.41B | $-26.38B |
| EPS | -880.00 | -880.00 | -812.00 | -1551.00 | -1401.03 |
| Gross Margin | 13.3% | 13.3% | 14.7% | 19.5% | 21.0% |
| Operating Margin | -426.2% | -426.2% | -299.3% | -257.0% | -324.4% |
| Net Margin | -430.4% | -430.4% | -262.7% | -233.8% | -300.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.02 | 0.01 | 0.03 |
| Current Ratio | 19.26 | 19.26 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-32.37B | $-32.37B | $-23.40B | $-22.07B | $-25.52B |
| Returns | |||||
| ROE | -88.3% | -88.3% | -48.1% | -48.1% | -82.2% |
| Valuation | |||||
| P/B | 28.89 | 28.89 | 2.73 | 1.22 | 3.89 |
| Growth & Yield | |||||
| Revenue Growth | -23.9% | -23.9% | 1.6% | 6.7% | — |
| EPS Growth | -8.4% | -8.4% | 47.6% | -10.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+142.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-812.00 → -880.00
Residual
+142.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.